A Phase 1 interventional study of [¹⁴C]-LY3337641 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-25.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated.
Participants will be admitted to a clinical research unit (CRU) the day before dosing. Participants remain confined to the CRU for at least 7 days. Participants may be discharged from the CRU any time after 7 days post-dose (Day 8), and up to a maximum of 21 days post-dose (Day 22).
This study will last approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 20 milligrams (mg) oral dose of LY3337641 containing 120 microcuries of radioactivity.
Drug: [¹⁴C]-LY3337641
Administered orally
Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Urinary excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in urine samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in urine and feces.
Time frame: Baseline up to 22 days
Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Fecal excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in fecal samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in feces.
Time frame: Baseline up to 22 days
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma LY3337641
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma Radioactivity
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Whole Blood Radioactivity
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma LY3337641
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma Radioactivity
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Whole Blood Radioactivity
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Pharmacokinetics: Total Number of Measurable Metabolites of LY3337641 in Plasma, Urine and Feces
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, and 312 hours postdose
| Milestone | 20mg [¹⁴C]-LY3337641 |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Urinary excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in urine samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in urine and feces.
| Percentage of total dose | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered | 2.9 ± 1.0 |
Fecal excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in fecal samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in feces.
| Percentage of total dose | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered | 86.4 ± 5.1 |
| Nanograms/milliliter (ng/mL) | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma LY3337641 | 77.9 ± 26 |
| nanogram equivalents/g (ng-equiv/g) | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma Radioactivity | 122 ± 25 |
| ng/mL | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Pharmacokinetics: Maximum Observed Concentration (Cmax) of Whole Blood Radioactivity | 67.5 ± 24 |
| Nanograms*hours per milliliter (ng*h/mL) | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma LY3337641 | 370 ± 25 |
| ng-equivalents*h/gram (ng-equiv*h/g) | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma Radioactivity | 1240 ± 51 |
| ng*h/mL | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Whole Blood Radioactivity | 5840 ± 105 |
| Number of Metabolites | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Plasma | 6 |
| Urine | 4 |
| Feces | 8 |
Collected over From Baseline to End of Study (Up to 29 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20 mg [¹⁴C]-LY3337641 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | 20 mg [¹⁴C]-LY3337641 |
|---|---|
| Abdominal discomfortGastrointestinal disorders | 1/6 |
| Change of bowel habitGastrointestinal disorders | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/6 |
| EcchymosisSkin and subcutaneous tissue disorders | 1/6 |
| Age, Continuous(Years) | 20mg [¹⁴C]-LY3337641 |
|---|---|
| Mean | 34.3 ± 11.4 |
| Sex: Female, Male(Participants) | 20mg [¹⁴C]-LY3337641 |
|---|---|
| Female | 0 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | 20mg [¹⁴C]-LY3337641 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 20mg [¹⁴C]-LY3337641 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | 20mg [¹⁴C]-LY3337641 |
|---|---|
| United States | 6 |
The record gives a start of Sep 2016, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2023, 6 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poseltinib